TrkC promotes survival and growth of leukemia cells through akt-mtor-dependent up-regulation of PLK-1 and Twist-1

Molecules and Cells

Volumn 36, Issue 2, 2013, Pages 177-184

  Kim, Min Soo ^a   Kim, Gyoung Mi ^a   Choi, Yun Jeong ^a   Kim, Hye Joung ^b   Kim, Yoo Jin ^b   Jin, Wook ^a  

^a Gachon University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Hematological Malignancies; Pi3k akt mtor; Survival And Growth; Trkc

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NEUROTROPHIN 3 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE 1; PROTEIN KINASE B; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR TWIST;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

APOPTOSIS; CELL CYCLE PROTEINS; CELL SURVIVAL; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; LEUKEMIA; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, TRKC; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TWIST TRANSCRIPTION FACTOR; U937 CELLS;

EID: 84892999662     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-013-0061-6     Document Type: Article

References (42)

1. Chen-Tsai, C.P., Colome-Grimmer, M., and Wagner, R.F., Jr. (2004). Correlations among neural cell adhesion molecule, nerve growth factor, and its receptors, TrkA, TrkB, TrkC, and p75, in perineural invasion by basal cell and cutaneous squamous cell carcinomas. Dermatol. Surg. 30, 1009-1016.
2. Cheng, G.Z., Chan, J., Wang, Q., Zhang, W., Sun, C.D., and Wang, L.H. (2007). Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67, 1979-1987.
3. Christiansen, D.H., Andersen, M.K., Desta, F., and Pedersen-Bjergaard, J. (2005). Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapyrelated myelodysplasia and acute myeloid leukemia. Leukemia 19, 2232-2240.
4. Cosset, E., Hamdan, G., Jeanpierre, S., Voeltzel, T., Sagorny, K., Hayette, S., Mahon, F.X., Dumontet, C., Puisieux, A., Nicolini, F.E., et al. (2011). Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood 117, 1673-1676.
5. Dong, F., Brynes, R.K., Tidow, N., Welte, K., Lowenberg, B., and Touw, I.P. (1995). Mutations in the gene for the granulocyte colonystimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N. Engl. J. Med. 333, 487-493.
6. Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., et al. (1999). Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93, 1355-1363.
7. Evangelisti, C., Ricci, F., Tazzari, P., Tabellini, G., Battistelli, M., Falcieri, E., Chiarini, F., Bortul, R., Melchionda, F., Pagliaro, P., et al. (2011). Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 25, 781-791.
8. Fenouille, N., Tichet, M., Dufies, M., Pottier, A., Mogha, A., Soo, J.K., Rocchi, S., Mallavialle, A., Galibert, M.D., Khammari, A., et al. (2012). The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 7, e40378.
9. Gleixner, K.V., Ferenc, V., Peter, B., Gruze, A., Meyer, R.A., Hadzijusufovic, E., Cerny-Reiterer, S., Mayerhofer, M., Pickl, W.F., Sillaber, C., et al. (2010). Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 70, 1513-1523.
10. Grotzer, M.A., Janss, A.J., Fung, K., Biegel, J.A., Sutton, L.N., Rorke, L.B., Zhao, H., Cnaan, A., Phillips, P.C., Lee, V.M., et al. (2000). TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J. Clin. Oncol. 18, 1027-1035.
11. Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G.T., Bene, M.C., De Vos, J., Hernandez, J.M., Hofmann, W.K., Mills, K.I., et al. (2010). Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 28, 2529-2537.
12. Hawkins, P.T., Anderson, K.E., Davidson, K., and Stephens, L.R. (2006). Signalling through class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647-662.
13. Hisaoka, M., Sheng, W.Q., Tanaka, A., and Hashimoto, H. (2002). Gene expression of TrkC (NTRK3) in human soft tissue tumours. J. Pathol. 197, 661-667.
14. Huang, E.J., and Reichardt, L.F. (2003). Trk receptors: roles in neuronal signal transduction. Ann. Rev. Biochem. 72, 609-642.
15. Ikezoe, T., Yang, J., Nishioka, C., Takezaki, Y., Tasaka, T., Togitani, K., Koeffler, H.P., and Yokoyama, A. (2009). A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 23, 1564-1576.
16. Jin, W., Yun, C., Kim, H.S., and Kim, S.J. (2007). TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res. 67, 9869-9877.
17. Jin, W., Kim, G.M., Kim, M.S., Lim, M.H., Yun, C., Jeong, J., Nam, J.S., and Kim, S.J. (2010). TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 31, 1939-1947.
18. Jin, W., Lee, J.J., Kim, M.S., Son, B.H., Cho, Y.K., and Kim, H.P. (2011). DNA methylation-dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 406, 89-95.
19. Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H., and Naoe, T. (1998). Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12, 1333-1337.
20. Knezevich, S.R., McFadden, D.E., Tao, W., Lim, J.F., and Sorensen, P.H. (1998). A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet. 18, 184-187.
21. Li, Z., Beutel, G., Rhein, M., Meyer, J., Koenecke, C., Neumann, T., Yang, M., Krauter, J., von Neuhoff, N., Heuser, M., et al. (2009). High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 113, 2028-2037.
22. Liu, Q., Schwaller, J., Kutok, J., Cain, D., Aster, J.C., Williams, I.R., and Gilliland, D.G. (2000). Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15) (p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 19, 1827-1838.
23. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
24. Manning, B.D., and Cantley, L.C. (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
25. McGregor, L.M., McCune, B.K., Graff, J.R., McDowell, P.R., Romans, K.E., Yancopoulos, G.D., Ball, D.W., Baylin, S.B., and Nelkin, B.D. (1999). Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc. Natl. Acad. Sci. USA 96, 4540-4545.
26. Min, Y.H., Eom, J.I., Cheong, J.W., Maeng, H.O., Kim, J.Y., Jeung, H.K., Lee, S.T., Lee, M.H., Hahn, J.S., and Ko, Y.W. (2003). Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17, 995-997.
27. Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., et al. (1998). RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12, 887-892.
28. Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet-Lefebvre, P., Willems, L., Green, A., Mayeux, P., Lacombe, C., and Bouscary, D. (2010). Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95, 819-828.
29. Puisieux, A., Valsesia-Wittmann, S., and Ansieau, S. (2006). A twist for survival and cancer progression. Br. J. Cancer 94, 13-17.
30. Renner, A.G., Creancier, L., Dos Santos, C., Fialin, C., Recher, C., Bailly, C., Kruczynski, A., Payrastre, B., and Manenti, S. (2010). A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway? Cell Cycle 9, 1690-1696.
31. Satoh, F., Mimata, H., Nomura, T., Fujita, Y., Shin, T., Sakamoto, S., Hamada, Y., and Nomura, Y. (2001). Autocrine expression of neurotrophins and their receptors in prostate cancer. Int. J. Urol. 8, S28-34.
32. Segal, R.A. (2003). Selectivity in neurotrophin signaling: theme and variations. Ann. Rev. Neurosci. 26, 299-330.
33. Segal, R.A., Goumnerova, L.C., Kwon, Y.K., Stiles, C.D., and Pomeroy, S.L. (1994). Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc. Natl. Acad. Sci. USA 91, 12867-12871.
34. Shimada, A., Taki, T., Tabuchi, K., Tawa, A., Horibe, K., Tsuchida, M., Hanada, R., Tsukimoto, I., and Hayashi, Y. (2006). KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 107, 1806-1809.
35. Song, G., Ouyang, G., and Bao, S. (2005). The activation of Akt/ PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9, 59-71.
36. Stommel, J.M., Kimmelman, A.C., Ying, H., Nabioullin, R., Ponugoti, A.H., Wiedemeyer, R., Stegh, A.H., Bradner, J.E., Ligon, K.L., Brennan, C., et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290.
37. Tang, J., Yang, X., and Liu, X. (2008). Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression. Oncogene 27, 6635-6645.
38. Tognon, C., Knezevich, S.R., Huntsman, D., Roskelley, C.D., Melnyk, N., Mathers, J.A., Becker, L., Carneiro, F., MacPherson, N., Horsman, D., et al. (2002). Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2, 367-376.
39. Vichalkovski, A., Gresko, E., Hess, D., Restuccia, D.F., and Hemmings, B.A. (2010). PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 29, 3554-3565.
40. Wai, D.H., Knezevich, S.R., Lucas, T., Jansen, B., Kay, R.J., and Sorensen, P.H. (2000). The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene 19, 906-915.
41. Xue, G., Restuccia, D.F., Lan, Q., Hynx, D., Dirnhofer, S., Hess, D., Ruegg, C., and Hemmings, B.A. (2012). Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov. 2, 248-259.
42. Yamashiro, D.J., Liu, X.G., Lee, C.P., Nakagawara, A., Ikegaki, N., McGregor, L.M., Baylin, S.B., and Brodeur, G.M. (1997). Expression and function of Trk-C in favourable human neuroblastomas. Eur. J. Cancer 33, 2054-2057.